echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's BRAF inhibitor approved in China for clinical treatment of colorectal cancer

    Pfizer's BRAF inhibitor approved in China for clinical treatment of colorectal cancer

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the information on the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, Pfizer's BRAF inhibitor encorafenib hard capsule has obtained an implied license for a clinical trial to develop a treatment for colorectal cancer.


    Colorectal cancer is one of the most common types of cancer in the world.


    Encorafenib is an oral BRAF inhibitor developed by Array Biopharma.


    In a phase 3 clinical study called BEACON CRC, researchers evaluated the effect of encorafenib combined with cetuximab in the treatment of patients with treated metastatic colorectal cancer with BRAF V600E mutation.


    It is worth mentioning that Pfizer is also exploring the effect of encorafenib and other drugs in the treatment of colorectal cancer.


    According to data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, there will be 1.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.